Navigation Links
Beating Blood Clots after Joint Replacement
Date:2/26/2009

Building awareness and understanding among patients is key

LAS VEGAS, Feb. 26 /PRNewswire-USNewswire/ -- As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication -- blood clots. According to findings released today at the 2009 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) (http://www.aaos.org/), deep vein thrombosis (DVT) (http://orthoinfo.aaos.org/topic.cfm?topic=A00219) a type of prophylaxis a patient receives pre and post-joint replacement, causes controversy.

"Patients undergoing total joint replacement are at high risk for DVT and pulmonary embolism (PE), unless they receive some form of prophylaxis (http://www.aaos.org/about/papers/advistmt/1027.asp)," stated Richard J. Friedman, MD, FRCSC, Clinical Professor of Orthopaedic Surgery at the Medical University of South Carolina, and Chairman, Department of Orthopaedic Surgery, Roper Hospital, in Charleston, SC. "The type of prophylaxis a patient may receive is often tailored on an individual basis, so there is not always a 'one-size fits all method' of prophylaxis available."

  • More than 700,000 primary total hip and knee replacements are performed each year in the United States, and that number is expected to grow to over 3.5 million in 2030.

On average, about 2-3 percent of people undergoing

SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
2. 10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs
3. US Testing Proves Glycn Go(TM) Increases NO in the Blood Stream
4. NicOx Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
5. Infant Blood May Provide Insights into Diseases Present at Birth
6. Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
7. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
10. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
11. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...ATAWAY, N.J., Dec. 1 Siemens Hear...ng) a leading global manufacturer of hearing instr...h Quota International,s Sound Beginnings program. ...010. ,, As part of the renewed partnership, Sie...for 100 free hearing instruments to both children ...
(Date:12/1/2009)...GO, Dec. 1 ADVENTRX Phar...ed that a new, recently completed preclinical stud...oxicity of ANX-514 and Taxotere® (docetaxel)....or ANX-514 in South Korea, independently conducted...dent confirmation of the bioequivalence and compar...
(Date:12/1/2009)...LE, Md., Dec. 1 Vanda Ph...y that the waiting period has expired under the Ha...f 1976 with respect to Vanda,s agreement, dated Oc...the agreement is now effective. Expiration of the...f the agreement, triggers an upfront payment to Va...
Breaking Medicine Technology:Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 1Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 2Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 3Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 4Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 5Boston Scientifics Urology Gynecology Products Featured in Studies at International Urogynecological Association Annual Meeting 48889 6HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 1HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 2HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 3HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research 48886 4Cynvec to Present at The 2009 New York Venture Summit 12624 1Cynvec to Present at The 2009 New York Venture Summit 12624 2
...7, 2007 /PRNewswire-FirstCall/ - Pacgen,Biopharmac...rt that,topline results from its Phase I/II study ...ly safe, well-tolerated, and active,in the treatme...tes,comparable to the current standard of care. Ba... a Phase IIb study to optimize PAC-113,dose and fo...
...RE)--May 7, 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, XS...developing novel therapeutics to treat cancer and ...its Phase II combretastatin A4,phosphate (CA4P) cl...was presented at the 47th Annual Meeting of the As...(ARVO) in Fort Lauderdale,FL. The abstract may be...
Other Medicine Technology:Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 2Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 3Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 4Pacgen Announces Positive Results from Phase I/II Trial of Novel,Antifungal Drug 5OXiGENE Announces a Poster Presentation Highlighting Results from,its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study,MMD-213) at the 47th Annual Meeting of the Association of Research,in Vision and Ophthalmology 2OXiGENE Announces a Poster Presentation Highlighting Results from,its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study,MMD-213) at the 47th Annual Meeting of the Association of Research,in Vision and Ophthalmology 3
(Date:12/1/2009)...HINGTON, Dec. 1 Individ...ore likely than those with traditional coverage to...be more engaged in wellness programs, and to be mo...ter in holding down costs, according to survey res...nefit Research Institute (EBRI). ,, At the sam...
(Date:12/1/2009)...RT LAUDERDALE, Fla., Dec. 1 OrbusN...ollment in the randomized clinical trial of the Co...Stent). ,, A prospective, randomized, multicent...f an ablu M inal sirolimus coat ED bio- E n... to 20 sites in Asia, Australia, Europe and South ...
(Date:12/1/2009)...ents in California are unable to successfully obta...ospitals despite recent state legislation intended... study. , Posing as low-income uninsured patient...than one-third of the hospitals they approached an...an those allowed under California law, according t...
(Date:12/1/2009)... Lumension announces general availability... to deliver end-to-end endpoint management capabil...management console architecture. , ...-- Lumension, a global leader in endpoint manageme...® Endpoint Management and Security Suite (LEMS...
(Date:12/1/2009)... , MILWAUKEE, Dec. 1 For ...s the ability to earn an income. It is this abil...t only pay today,s mortgage but also to plan and s...,, Yet, according to a Northwestern Mutual s...have taken measures to protect their income by ins...
Breaking Medicine News(10 mins):Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:Hospital price transparancy laws in California fall short, study finds 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 2Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 3Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 4Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 5Health News:New Lumension Endpoint Management and Security Suite To Deliver End-to-End Endpoint Management Capabilities 6Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 2Health News:Northwestern Mutual Survey Reveals That Most Americans Are Putting Their Income at Risk 3
...-in-law has revealed that the star had a miscarria...ounding Moore and hubby Ashton Kutcher ever since ...ey Guynes has revealed to American magazine Star t...on have been trying (to have a child) for years. S...
... PETA has commended Sir Paul McCartney for his dec...mals . The former Beatle, who has supporte... of the disease in 1998, recently revealed that he...ng that a number of charities close to his heart p...
...have confirmed a long-standing belief that male ci...y 60 percent, an international AIDS conference wil...-chairman of an International AIDS Society (IAS) c...ys knew that if you went into any particular Afric...
...f India say there is an alarming depletion of grou... model legislation to prevent further erosion of w...s carried out a survey to find out the ground wate...The constant mining of ground water reserves and t...
...d left-handers, natural lefties who have switched ...t changes the way their brains are organized, and...searchers say while some areas in such peoples bra...ts suffer because of this extra attention that the...
... Novartis AG has been given the green light from t...pean market, Galvus has nevertheless still no acc...ion by a committee of experts at the European Medi...ty data. Galvus is said to work in a similar...
Other Medicine News:Health News:Male Circumcision can Cut HIV Infection, Studies Show 2Health News:Groundwater Levels Depleting Alarmingly in India 2Health News:Converting Left-hander to Right-hander also Changes the Brain 2
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
...oratories is a national reference laboratory and a...h and development. ARUP offers an extensive test m...clinical and anatomic pathology. Owned by the Univ... more than half of the nation's university teachin...
Medicine Products: